These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29193967)

  • 1. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
    Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
    J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
    Chen X; Xu W; Wang K; Mo M; Zhang W; Du L; Yuan X; Xu Y; Wang Y; Shen J
    J Med Chem; 2015 Nov; 58(21):8529-41. PubMed ID: 26479945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
    Woolford AJ; Day PJ; Bénéton V; Berdini V; Coyle JE; Dudit Y; Grondin P; Huet P; Lee LY; Manas ES; McMenamin RL; Murray CW; Page LW; Patel VK; Potvain F; Rich SJ; Sang Y; Somers DO; Trottet L; Wan Z; Zhang X
    J Med Chem; 2016 Dec; 59(23):10738-10749. PubMed ID: 27933945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
    Chen X; Wang K; Xu W; Ma Q; Chen M; Du L; Mo M; Wang Y; Shen J
    J Med Chem; 2016 Mar; 59(6):2674-87. PubMed ID: 26927682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
    Woolford AJ; Pero JE; Aravapalli S; Berdini V; Coyle JE; Day PJ; Dodson AM; Grondin P; Holding FP; Lee LY; Li P; Manas ES; Marino J; Martin AC; McCleland BW; McMenamin RL; Murray CW; Neipp CE; Page LW; Patel VK; Potvain F; Rich S; Rivero RA; Smith K; Somers DO; Trottet L; Velagaleti R; Williams G; Xie R
    J Med Chem; 2016 Jun; 59(11):5356-67. PubMed ID: 27167608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
    Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
    J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
    Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y
    J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
    Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.
    Wang K; Xu W; Zhang W; Mo M; Wang Y; Shen J
    Bioorg Med Chem Lett; 2013 May; 23(10):2897-901. PubMed ID: 23575276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein-associated phospholipase A2: The story continues.
    Huang F; Wang K; Shen J
    Med Res Rev; 2020 Jan; 40(1):79-134. PubMed ID: 31140638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
    Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
    Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
    Pemberton N; Mogemark M; Arlbrandt S; Bold P; Cox RJ; Gardelli C; Holden NS; Karabelas K; Karlsson J; Lever S; Li X; Lindmark H; Norberg M; Perry MWD; Petersen J; Rodrigo Blomqvist S; Thomas M; Tyrchan C; Westin Eriksson A; Zlatoidsky P; Öster L
    J Med Chem; 2018 Jun; 61(12):5435-5441. PubMed ID: 29852070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.
    Boyd HF; Fell SC; Hickey DM; Ife RJ; Leach CA; Macphee CH; Milliner KJ; Pinto IL; Rawlings DA; Smith SA; Stansfield IG; Stanway SJ; Theobald CJ; Whittaker CM
    Bioorg Med Chem Lett; 2002 Jan; 12(1):51-5. PubMed ID: 11738571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
    Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
    J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
    Riley RF; Corson MA
    IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
    Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
    J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.
    Jeong TS; Kim MJ; Yu H; Kim KS; Choi JK; Kim SS; Lee WS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1525-7. PubMed ID: 15713421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
    Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
    J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).
    Brnardic EJ; Ye G; Brooks C; Donatelli C; Barton L; McAtee J; Sanchez RM; Shu A; Erhard K; Terrell L; Graczyk-Millbrandt G; He Y; Costell MH; Behm DJ; Roethke T; Stoy P; Holt DA; Lawhorn BG
    J Med Chem; 2018 Nov; 61(21):9738-9755. PubMed ID: 30335378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of bioavailable inhibitors of secretory phospholipase A2.
    Blanchard SG; Andrews RC; Brown PJ; Gan LS; Lee FW; Sinhababu AK; Wheeler TN
    Pharm Biotechnol; 1998; 11():445-63. PubMed ID: 9760691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.